European consensus for the diagnosis of Alzheimer’s disease

This diagnostic pathway has been developed on the basis of the scientific literature and from the practical experience of the specialists. HUG - A team from the University of Geneva, the HUG and the IRCCS has drawn up recommendations for the effective and individualised use of biomarkers in memory clinics for the diagnosis of Alzheimer's disease. A multidisciplinary working group of 22 experts from eleven European scientific associations have joined forces to define recommendations for the effective and individualized use of biomarkers for the diagnosis of Alzheimer's disease in memory clinics. Putting patients, instead of the disease or a test, at the center of doctors' diagnostic considerations constitutes a turning point in the approaches currently applied. This work has been coordinated by a team from the University Hospital of Geneva (HUG), the University of Geneva and the Fatebenefratelli of Brescia National Research Center for Alzheimer's Disease (IRCCS). The consensus is published in The Lancet Neurology . Experts from eleven European scientific associations and organizations and a patient advocacy association (Alzheimer Europe) have collaborated to define a diagnostic pathway focused on each individual case which enables the right tests to be identified according to the symptoms profile.